SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
Date of
report (Date of earliest event reported): May 16, 2005
Neurologix,
Inc.
(Exact
name of registrant as specified in its charter)
|
DELAWARE |
000-13347 |
06-1582875 |
|
(State
or other jurisdiction of |
(Commission |
I.R.S.
Employer |
|
incorporation
or organization) |
File
Number) |
Identification
No.) |
|
ONE
BRIDGE PLAZA, FORT LEE, NEW JERSEY |
07024 |
|
(Address
of principal executive offices) |
(Zip
Code) |
|
(201)
592-6451 |
|
(Registrant’s
telephone number,
including
area code) |
|
None |
|
(Former
name, former address and former fiscal year, |
|
if
changed since last report) |
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
[
] |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
[
] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
[
] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
[
] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item
2.02 Results
of Operations and Financial Condition.
On May
16, 2005, the Registrant announced its earnings for its first quarter ended
March 31, 2005. A copy of the press release of the Registrant is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
The
information, including the exhibit attached hereto, in this Current Report is
being furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any registration statement or
other document pursuant to the Securities Act of 1933, as amended, except as
otherwise expressly stated in such filing.
Item
7.01 Regulation
FD Disclosure.
On May
16, 2005, the Registrant announced its earnings for its first quarter ended
March 31, 2005. A copy of the press release of the Registrant is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
The
information, including the exhibit attached hereto, in this Current Report is
being furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any registration statement or
other document pursuant to the Securities Act of 1933, as amended, except as
otherwise expressly stated in such filing.
Item
9.01 Financial
Statements and Exhibits.
(c) Exhibits.
See
Exhibit Index below.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
NEUROLOGIX,
INC. |
| |
|
|
Dated:
May 17, 2005 |
By:/s/
Mark S. Hoffman |
| |
Name:
Mark S. Hoffman |
| |
Title:
Secretary and Treasurer |
EXHIBIT
INDEX
|
Exhibit
No. |
Description |
|
99.1 |
Press
Release, dated May 16, 2005 (furnished
herewith) |